Navigation Links
Iomai Reports 'Going Concern' Qualification in 10-K
Date:3/28/2008

GAITHERSBURG, Md., March 28 /PRNewswire-FirstCall/ -- Iomai Corporation (Nasdaq: IOMI) today announced, in compliance with NASDAQ marketplace rules, that the independent audit report included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 27, 2008 for the fiscal year ended December 31, 2007 contained a "going concern" qualification. This disclosure is required under NASDAQ marketplace rules and does not represent any change to the Company's Annual Report on Form 10-K for the year ended December 31, 2007 and filed on March 27, 2008 with the SEC.

ABOUT IOMAI CORPORATION

Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI, discovered by researchers at the Walter Reed Army Institute of Research, taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin (Langerhans cells) to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, develop new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. Iomai currently has four product candidates in development: three targeting influenza and pandemic flu and one to prevent travelers' diarrhea. For more information on Iomai, please visit http://www.iomai.com.


'/>"/>
SOURCE Iomai Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Study Finds Single Dose of Iomai Patch With Pandemic Flu Vaccine Achieves Protective Levels
2. Iomai CEO to Speak at Cowen and Company Health Care Conference on Monday, March 17
3. Iomai Study Shows Self-Applied Travelers Diarrhea Vaccine Patch Comparable to Clinician-Applied Vaccine Patch
4. Iomai Patch-Based Vaccine Cut Rate of Travelers Diarrhea by 75 Percent in Phase 2 Field Study
5. Hospital for Special Surgery Reports Scores on HCAHPS Survey
6. PreMD Reports Fiscal 2007 Results
7. Interleukin Genetics Reports Fourth Quarter and Year End 2007 Financial Results
8. CryoCor Reports Going Concern Statement and Receives Notification From Nasdaq Relating to Minimum Stockholders Equity
9. Spheris Reports Fourth Quarter and Year-End 2007 Results
10. NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results
11. QMed, Inc. Reports Year-End and Fourth Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... NJ (PRWEB) , ... April 28, 2017 , ... Horizon ... has affirmed the company’s credit rating of “A” and its outlook as “stable.” At ... if capital reserves, which have fallen in recent years, dip below “capital adequacy” thresholds ...
(Date:4/28/2017)... York, NY (PRWEB) , ... April 28, 2017 ... ... Medical Laboratory to expanded distribution of the GlycoMark test throughout the Northeast U.S. ... recent hyperglycemia in patients with diabetes. The GlycoMark test provides a clinically proven ...
(Date:4/28/2017)... ... 2017 , ... Ushio America proudly introduces the new ... solution for F32T8 fluorescent lamps on most instant-start and programmed-start electronic ballasts so ... lamps utilize the existing electronic ballast, saving labor and maintenance costs. It’s easy ...
(Date:4/28/2017)... New york (PRWEB) , ... April 28, 2017 ... ... pleased to announce that Aditya Patel M.D. has joined the revolutionary endoscopic practice ... training and board certification in Interventional Pain Medicine. The patented, revolutionary eDiscSculpt Technique ...
(Date:4/28/2017)... ... 2017 , ... The Texas Cord Blood Bank (TCBB), a program of nonprofit ... at Women’s Hospital at Renaissance in Edinburg for their outstanding efforts in collecting umbilical ... to donate. , “Women’s Hospital at Renaissance has been a collection partner for ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  Cogentix Medical, ... focused on providing the Urology, Uro/Gyn and Gynecology ... that Ash Keswani has joined the Company as ... this newly created position, Mr. Keswani will report ... CEO. "Our organization is delighted that ...
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ABBV), ... percent (n=145/146) of chronic hepatitis C virus (HCV) ... or 6 and compensated cirrhosis (Child-Pugh A) achieved ... 12 ) with its investigational, pan-genotypic regimen of ... were seen following 12 weeks of G/P treatment ...
Breaking Medicine Technology: